AstraZeneca, Daiichi Sankyo report positive results from DESTINY-Breast06 phase III trial of Enhertu

The DESTINY-Breast06 phase III trial unveiled positive outcomes, showing Enhertu's (trastuzumab deruxtecan) significant progression-free survival (PFS) improvement over standard chemotherapy in HR-positive, HER2-low metastatic breast cancer post-endocrine therapy.

Results also revealed notable PFS gains across the overall patient population, encompassing HER2-low and HER2-ultralow subgroups. Enhertu's safety profile remained consistent with previous breast cancer trials.

Developed by AstraZeneca and Daiichi Sankyo, Enhertu addresses an unmet need in HER2-low breast cancer. Pre-approval, targeted therapies for HER2-low expression were scarce, and there are currently none for HER2-ultralow expression.

The ongoing trial will assess overall survival (OS) and other secondary endpoints. HER2-low breast cancer constitutes a significant proportion of HR-positive, HER2-negative cases, highlighting Enhertu's potential impact.